CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV

Clinical Infectious Diseases

Volumn 57, Issue 2, 2013, Pages 314-321

  Helleberg, Marie ^a   Kronborg, Gitte ^b   Larsen, Carsten S ^c   Pedersen, Gitte ^d   Pedersen, Court ^e   Obel, Niels ^a   Gerstoft, Jan ^a  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cancer; cardiovascular disease; HIV; lymphocyte count; mortality

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE;

ADULT; ARTICLE; CANCER RISK; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DEATH; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

CANCER; CARDIOVASCULAR DISEASE; HIV; LYMPHOCYTE COUNT; MORTALITY;

ADULT; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84879673824     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit232     Document Type: Article

References (23)

1. Touloumi G, Pantazis N, Pillay D, et al. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline and viral load set point in European seroconverter cohorts. Clin Infect Dis 2013 56:888-97.
2. Lodi S, Phillips A, Touloumi G, et al. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS 2010; 24:2697-704.
3. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010; 24:614-7.
4. Bohlius J, Schmidlin K, Boue F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. Blood 2011; 117:6100-8.
5. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001; 410:974-9.
6. Catalfamo M, Di MM, Hu Z, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A 2008; 105:19851-6.
7. Kipps TJ. Lymphocytosis and lymphocytopenia.Williams Hematology. 7th ed. New York: McGraw-Hill Education; 2006.
8. Nunez J, Sanchis J, Bodi V, et al. Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes. Eur J Intern Med 2009; 20:768-74.
9. Gul M, Uyarel H, Ergelen M, et al. Predictive value of neutrophil to lymphocyte ratio in clinical outcomes of non-ST elevation myocardial infarction and unstable angina pectoris: A 3-year follow-up [published online ahead of print 8 November 2012]. Clin Appl Thromb Hemost 2012; PMID: 23144177.
10. Nunez J, Minana G, Bodi V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem 2011; 18:3226-33.
11. Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004; 19:135-40.
12. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol 2009; 38:1202-6.
13. The Central Office of Civil Registration. Available at: www.crp.dk. Accessed 15 September 2011.
14. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46:263-8.
15. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997; 44:535-9.
16. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIVinfected patients. AIDS 2010; 24:1877-86.
17. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: A longitudinal cohort study from COHERE. PLoS Med 2012; 9:e1001194.
18. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130:570-7.
19. Helleberg M, Kronborg G, Larsen CS, et al. Causes of death among Danish HIV patients compared with population controls in the period 1995-2008. Infection 2012; 40:627-34.
20. Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569-75.
21. Kofoed K, Gerstoft J, Mathiesen LR, Benfield T. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis 2006; 33:143-8.
22. Turett GS, Telzak EE. Normalization of CD4+ T-lymphocyte depletion in patients without HIV infection treated for tuberculosis. Chest 1994; 105:1335-7.
23. Worm SW, Hsue P. Role of biomarkers in predicting CVD risk in the setting of HIV infection? Curr Opin HIVAIDS 2010; 5:467-72.